E-LIB Suche - Ergebnisse für: Homayoun Roshanisefat

1

Cannabis-Based Medicine for Neuropathic Pain and Spasticity..:

Hansen, Julie Schjødtz ; Gustavsen, Stefan ; Roshanisefat, Homayoun...
Pharmaceuticals. 16 (2023) 8 - p. 1079 , 2023

Link: https://doi.org/10.3390/..

2

Real-world outcomes for a complete nationwide cohort of mor..:

Papp, Viktoria ; Buron, Mathias Due ; Siersma, Volkert...
PLOS ONE. 16 (2021) 5 - p. e0250820 , 2021

Link: https://doi.org/10.1371/..

3

Comparative effectiveness of teriflunomide and dimethyl fum..:

Buron, Mathias Due ; Chalmer, Thor Ameri ; Sellebjerg, Finn...
Neurology. 92 (2019) 16 - p. , 2019

Link: https://doi.org/10.1212/..

4

Multiple sclerosis course and clinical outcomes in patients..:

Manouchehrinia, Ali ; Edwards, Laura J ; Roshanisefat, Homayoun..
BMJ Open. 5 (2015) 5 - p. e007806 , 2015

Link: https://doi.org/10.1136/..

5

Cannabis-Based Medicine for Neuropathic Pain and Spasticity..:

Julie Schjødtz Hansen ; Stefan Gustavsen ; Homayoun Roshanisefat...
Pharmacology. , 2023

Link: https://doi.org/10.3390/..

6

Cannabis-Based Medicine for Neuropathic Pain and Spasticity..:

Julie Schjødtz Hansen ; Stefan Gustavsen ; Homayoun Roshanisefat...
https://www.mdpi.com/1424-8247/16/8/1079. , 2023

Link: https://doi.org/10.3390/..

7

Real-world outcomes for a complete nationwide cohort of mor..:

Viktoria Papp ; Mathias Due Buron ; Volkert Siersma...
https://doi.org/10.1371/journal.pone.0250820. , 2021

Link: https://doi.org/10.1371/..

8

Characteristics of the treatment naïve and previously treat..:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/dataset/Characteristics_of_the_treatment_na_ve_and_previously_treated_subgroup_at_teriflunomide_treatment_start_/14612509. , 2021

Link: https://doi.org/10.1371/..

9

One-year follow-up and risk factors for adverse event and t..:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/journal_contribution/One-year_follow-up_and_risk_factors_for_adverse_event_and_treatment_escalation_/14612494. , 2021

Link: https://doi.org/10.1371/..

10

Baseline characteristics of patients starting teriflunomide..:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/figure/Baseline_characteristics_of_patients_starting_teriflunomide_treatment_between_2013_2019_in_Denmark_/14612500. , 2021

Link: https://doi.org/10.1371/..

11

Temporal changes in the use of teriflunomide in Denmark:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/journal_contribution/Temporal_changes_in_the_use_of_teriflunomide_in_Denmark_/14612491. , 2021

Link: https://doi.org/10.1371/..

12

Teriflunomide discontinuations and treatment switches durin..:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/dataset/Teriflunomide_discontinuations_and_treatment_switches_during_the_study_period_2013_2019_/14612515. , 2021

Link: https://doi.org/10.1371/..

13

Characteristics of the study population at teriflunomide tr..:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/dataset/Characteristics_of_the_study_population_at_teriflunomide_treatment_start_/14612506. , 2021

Link: https://doi.org/10.1371/..

14

Long-term follow-up of patient started on teriflunomide bet..:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/figure/Long-term_follow-up_of_patient_started_on_teriflunomide_between_2013_and_2019_/14612503. , 2021

Link: https://doi.org/10.1371/..

15

Confirmed disability worsening:

Viktoria Papp (6001190) ; Mathias Due Buron (10818685) ; Volkert Siersma (848218)...
https://figshare.com/articles/dataset/Confirmed_disability_worsening_/14612512. , 2021

Link: https://doi.org/10.1371/..